A Rational Approach to the Management of Recurrent or Persistent Ovarian CarcinomaTHIGPEN, TATE MDClinical Obstetrics & Gynecology: March 2012 - Volume 55 - Issue 1 - p 114–130 doi: 10.1097/GRF.0b013e31824b9bc5 Ovarian Cancer Abstract Author Information Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent. Division of Oncology, University of Mississippi Medical Center, Jackson, Mississippi The author declares that he has nothing to disclose. Correspondence: Tate Thigpen, MD, Division of Oncology, University of Mississippi Medical Center, Jackson, MS. E-mail: firstname.lastname@example.org © 2012 Lippincott Williams & Wilkins, Inc.